|Doug Harrington, MD|
Aviir Inc, Irvine, Calif, is extending its services with a comprehensive inherited cardiovascular disease genetic test menu.
The newly validated tests cover the major causes of cardiomyopathies, arrhythmia disorders, and other genetically transmitted diseases that affect the heart and vasculature.
Each test is available for testing in both individual and familial settings. Two comprehensive panels are available to check for undiagnosed arrhythmia or cardiomyopathy.
“Aviir’s mission is to identify and prevent cardiovascular diseases, and subsequent deaths, through the best diagnostic means available,” says Doug Harrington, MD, CEO, Aviir, noting the company’s expanded testing options. “This type of testing can be the difference between effective disease management and needless risk of sudden cardiac death. The novel approach Aviir has taken to identify disease-causing genetic variants allows for not only an unprecedented level of thoroughness (ie, 100% coverage of the disease-causing genes), but also for unmatched speed in returning results to physicians and patients.”
Genetic testing can help determine a successful course of treatment for the patient, as well as identify any familial testing needs resulting from a positive result. In many instances the first indication that an individual is affected is sudden cardiac death, hence, testing is key to preventing a catastrophic event. This information can lead a patient to make successful lifestyle changes and pursue therapy to live a healthy and successful life despite the disease.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development, and commercialization of innovative diagnostic tests. The company specializes in developing proprietary diagnostic tests to assist in identifying patients who are at high risk for the development of a cardiac event. Its proprietary MIRISK and MIRISK VP assessments objectively identify, using a single blood draw, individuals who are at a high risk of experiencing a cardiac event over the next 5 years. The company’s CLIA-certified laboratory complements these tests with a wide range of additional tests for heart health assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders – including pharmacogenomic and genetic tests.